Fluent Financial, LLC Exact Sciences Corp Transaction History

Fluent Financial, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$72.5 - $100.68 $242,150 - $336,271	-3,340 Closed	0 $0
Q3 2021 Oct 19, 2021	SELL	$90.24 - $124.05 $12,633 - $17,367	-140 Reduced 4.02%	3,340 $319,000
Q2 2021 Aug 03, 2021	SELL	$93.66 - $139.27 $31,750 - $47,212	-339 Reduced 8.88%	3,480 $433,000
Q4 2020 Jan 22, 2021	BUY	$99.61 - $142.12 $13,945 - $19,896	140 Added 3.81%	3,819 $506,000
Q3 2020 Oct 16, 2020	SELL	$72.92 - $102.01 $24,792 - $34,683	-340 Reduced 8.46%	3,679 $375,000
Q2 2020 Jul 15, 2020	SELL	$55.75 - $92.75 $19,791 - $32,926	-355 Reduced 8.12%	4,019 $349,000
Q1 2020 Apr 28, 2020	BUY	$37.9 - $104.44 $11,370 - $31,332	300 Added 7.36%	4,374 $254,000
Q4 2018 Feb 08, 2019	SELL	$56.04 - $82.66 $22,416 - $33,064	-400 Reduced 8.94%	4,074 $257,000
Q3 2018 Oct 29, 2018	SELL	$48.29 - $80.6 $20,088 - $33,529	-416 Reduced 8.51%	4,474 $353,000
Q2 2018 Aug 07, 2018	BUY	$37.84 - $69.96 $185,037 - $342,104	4,890 New	4,890 $292,000
Q1 2018 Apr 24, 2018	SELL	$39.82 - $57.53 $194,719 - $281,321	-4,890 Closed	0 $0
Q4 2017 Feb 12, 2018	BUY	$46.49 - $60.51 $227,336 - $295,893	4,890	4,890 $244,000

673

162M

2.58M

2.19M

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $10.2B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

Get notified when there are updates to the investment portfolio of Fluent Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Fluent Financial, LLC with notifications on news.